Pozen shares drop on CRL; manufacturing issues are cited
By Jennifer Boggs
Monday, April 28, 2014
Pozen Inc. said it expects to fully address the third-party manufacturing issues raised in the FDA's complete response letter (CRL) for drug candidates PA8140/PA32540, but the latest delay for the gastrointestinal-friendly aspirin candidates opened the door for investor anxiety, including concerns that the company's strategy of combining two generic components might not make for a commercial success story.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.